The Future of IDMP: From Regulatory Compliance to Connected Product Data
Identification of Medicinal Products (IDMP) is more than a regulatory requirement. It presents an opportunity for biopharmaceutical organizations to transform fragmented product information into a trusted, connected data foundation that supports regulatory compliance and drives value across the enterprise.
As regulatory authorities advance toward more structured, data-driven approaches, organizations must look beyond technology implementation to address data quality, governance and cross-functional integration. With IDMP and electronic Common Technical Document (eCTD) 4.0 requirements evolving in parallel, coordinated planning is essential to building sustainable capabilities and avoiding duplicated efforts.
In this white paper, Syneos Health experts explore how organizations can move beyond compliance-focused initiatives to establish a connected product-data strategy.
Key insights include:
- The current state of IDMP: Understand evolving global regulatory expectations and the implications for product-data management
- The path to readiness: Explore a phased roadmap for strengthening data governance, integrating systems and preparing for structured regulatory exchange
- Common implementation challenges: Identify barriers related to fragmented data, inconsistent standards and unclear ownership
- Opportunities beyond compliance: Discover how connected product data can support pharmacovigilance, supply visibility, regulatory efficiency and responsible artificial intelligence (AI) adoption
Download the article to explore practical steps for advancing IDMP readiness, strengthening enterprise-wide data governance and turning regulatory requirements into lasting business value.
Related Content
Looking for exclusive insight?
